AEON Biopharma
AEON
71 hedge funds and large institutions have $202M invested in AEON Biopharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 10 closing their positions.
5% more capital invested
Capital invested by funds: $192M → $202M (+$10.3M)
0.05% more ownership
Funds ownership: 0.99% → 1.04% (+0.05%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
3% less funds holding
Funds holding: 73 → 71 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$9.74M |
| 2 |
SC
Sculptor Capital
New York
|
+$4.67M |
| 3 |
SCM
Saba Capital Management
New York
|
+$4.21M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.47M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$4.99M |
| 2 |
Blackstone Inc
New York
|
-$4.48M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.76M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.06M |
| 5 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$1.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
76
Covalis Capital
London,
United Kingdom
| – | -$1.22M | -1,736 | Closed |
|
|
CCFM
77
Cohen & Co Financial Management
New York
| – | -$971K | -1,389 | Closed |
|
|
QGA
78
Q Global Advisors
Fort Worth,
Texas
| – | -$713K | -1,020 | Closed |
|
79
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$165K | -235 | Closed |
|
|
PCM
80
Pinz Capital Management
New York
| – | -$138K | -197 | Closed |
|
|
TRCT
81
Tower Research Capital (TRC)
New York
| – | -$2K | -2 | Closed |
|
AEON Hedge Fund Activity: Q1 2022 in Review
71 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2022, worth a combined $202M — up 5.4% from $192M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AEON and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $9.74M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.99M sold.
- 71 institutional investors held AEON Biopharma (AEON) as of Q1 2022, down from 73 in Q4 2021.
- Funds reported $202M of AEON Biopharma stock for Q1 2022, up 5.4% quarter-over-quarter.
- 8 funds opened new AEON Biopharma positions in Q1 2022 and 10 closed out, a net change of -2 holders.
- The largest AEON Biopharma buyer in Q1 2022 was Aristeia Capital, an estimated $9.74M added.
- The largest AEON Biopharma seller in Q1 2022 was UBS O'Connor, an estimated $4.99M sold.
Based on aggregated 13F filings for Q1 2022.